This PDF is the current document as it appeared on Public Inspection on 06/06/2014 at 08:45 am.
Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Fax written comments on the collection of information by July 9, 2014.
To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-7285, or emailed to email@example.com. All comments should be identified with the OMB control number 0910-0687. Also include the FDA docket number found in brackets in the heading of this document.Start Further Info
FOR FURTHER INFORMATION CONTACT:
FDA PRA Staff, Office of Operations, Food and Drug Administration, 8455 Colesville Rd., COLE-14526, Silver Spring, MD 20993-0002, PRAStaff@fda.hhs.gov.End Further Info End Preamble Start Supplemental Information
In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
Testing Communications on Biological Products—(OMB Control Number 0910-0687)—Extension
FDA is authorized by section 1003(d)(2)(D) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 393(d)(2)(D)) to conduct educational and public information programs relating to the safety of regulated biological products. FDA conducts needed research to help ensure that such programs have the highest likelihood of being effective. FDA expects that improving communications about biological products will involve many research methods, including individual indepth interviews, mall-intercept interviews, focus groups, self-administered surveys, gatekeeper reviews, and omnibus telephone surveys. The information will be used to explore concepts of interest and assist in the development and modification of communication messages and campaigns to fulfill the Agency's mission to protect the public health.
The information collected will serve three major purposes. First, as formative research it will provide critical knowledge needed about target audiences to develop messages and campaigns about biological product use. Knowledge of consumer and health care professional decisionmaking processes will provide the better understanding of target audiences that FDA needs to design effective communication strategies, messages, and labels. These communications will aim to improve public understanding of the risks and benefits of using biological products by providing users with a better context in which to place risk information more completely.
Second, as initial testing, it will allow FDA to assess the potential effectiveness of messages and materials in reaching and successfully communicating with their intended audiences. Testing messages with a sample of the target audience will allow FDA to refine messages while still in the developmental stage. Respondents will be asked to give their reaction to the messages in either individual or group settings.
Third, as evaluative research, it will allow FDA to ascertain the effectiveness of the messages and the distribution method of these messages in achieving the objectives of the message campaign. Evaluation of campaigns is a vital link in continuous improvement of communications at FDA.
In the Federal Register of October 1, 2013 (78 FR 60287), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.
FDA estimates the burden of this collection of information based on prior experience with the various types of data collection methods described in this document:Start Printed Page 32964
|21 U.S.C. Section 393(d)(2)(D) (various data collection methods)||Number of respondents||Number of responses per respondent||Total annual responses||Average burden per response||Total hours|
|Individual Indepth Interviews||360||1||360||0.75 (45 minutes)||270|
|General Public Focus Group Interviews||288||1||288||1.50 (90 minutes)||432|
|Intercept Interviews: Central Location||200||1||200||0.25 (15 minutes)||50|
|Intercept Interviews: Telephone||4,000||1||4,000||0.08 (5 minutes)||320|
|Self-Administered Surveys||2,400||1||2,400||0.25 (15 minutes)||600|
|Gatekeeper Reviews||400||1||400||0.50 (30 minutes)||200|
|Omnibus Surveys||1,200||1||1,200||0.17 (10 minutes)||204|
|Total (General Public)||8,848||1||8,848||2,076|
|Physician Focus Group Interviews||432||1||432||1.50 (90 minutes)||648|
|Total (Overall)||9,280||1||9,280||0.29 (17 minutes)||2,724|
Dated: June 3, 2014.
Assistant Commissioner for Policy.
[FR Doc. 2014-13292 Filed 6-6-14; 8:45 am]
BILLING CODE 4160-01-P